Fructooligosaccharides enhance the therapeutic effect of xiao-zhi-fang on non-alcoholic fatty liver disease via regulating intestinal flora*

被引:4
作者
Zhang, Jiongshan [1 ]
Li, Yue [1 ]
Xiao, Gemin [1 ]
Li, Yongwei [1 ]
Xie, Heping [1 ]
Chen, Yan [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Tradit Chinese Med, Guangzhou, Peoples R China
关键词
Fructooligosaccharides (FOS); High -fat diet (HFD); Intestinal flora; Non-alcoholic fatty liver disease (NAFLD); Xiao-zhi-fang (XZF); AKKERMANSIA-MUCINIPHILA; HEALTH; NAFLD; MICROBIOTA; OBESITY; PROFILE;
D O I
10.1016/j.livres.2021.06.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) is a frequently occurring clinical disease, which could be treated by traditional Chinese medicine. However, the effects and mechanisms of xiao-zhi-fang (XZF) alone or in combination with fructooligosaccharides (FOS) on NAFLD remains unclear. Methods: This study established the NAFLD mouse model by feeding with a high-fat diet and by administering with XZF and/or FOS. Moreover, the fat content in the liver tissues was evaluated by oil red O and hematoxylin and eosin staining, and the liver function indices were examined using a biochemical analyzer. Changes in the intestinal flora were monitored using 16S rRNA gene sequencing. The results of the current study showed that the alanine aminotransferase, aspartate aminotransferase, total triglyceride, total cholesterol levels, and the amount of lipid accumulation were markedly elevated in NAFLD mice. Results: XZF alone or in combination with FOS significantly reduced lipid accumulation in the liver and blood lipid levels in NAFLD mice. Moreover, XZF alone or in combination with FOS notably altered the intestinal flora structure in NAFLD mice. Consequently, 17 operational taxonomic units were decreased and nine were increased in the XZF and/or FOS groups. Conclusions: FOS may accelerate the intestinal microecological balance in NAFLD mice after treatment with XZF by promoting intestinal flora growth, thereby enhancing the therapeutic effect of XZF on NAFLD. & COPY; 2021 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:217 / 223
页数:7
相关论文
共 46 条
  • [1] Pathology of non-alcoholic fatty liver disease
    Bedossa, Pierre
    [J]. LIVER INTERNATIONAL, 2017, 37 : 85 - 89
  • [2] Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic Preface
    Bernstein, David E.
    [J]. CLINICS IN LIVER DISEASE, 2018, 22 (01) : XIII - XIV
  • [3] NAFLD, Helicobacter species and the intestinal microbiome
    Castano-Rodriguez, Natalia
    Mitchell, Hazel M.
    Kaakoush, Nadeem O.
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2017, 31 (06) : 657 - 668
  • [4] The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
    Chalasani, Naga
    Younossi, Zobair
    Lavine, Joel E.
    Charlton, Michael
    Cusi, Kenneth
    Rinella, Mary
    Harrison, Stephen A.
    Brunt, Elizabeth M.
    Sanyal, Arun J.
    [J]. HEPATOLOGY, 2018, 67 (01) : 328 - 357
  • [5] Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease
    Chen, Ze
    Yu, Yao
    Cai, Jingjing
    Li, Hongliang
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2019, 30 (12) : 903 - 914
  • [6] Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters
    Cobbina, Enoch
    Akhlaghi, Fatemeh
    [J]. DRUG METABOLISM REVIEWS, 2017, 49 (02) : 197 - 211
  • [7] Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
    Cole, Banumathi K.
    Feaver, Ryan E.
    Wamhoff, Brian R.
    Dash, Ajit
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (02) : 193 - 205
  • [8] A network pharmacology approach to investigate the anti-inflammatory mechanism of effective ingredients from Salvia miltiorrhiza
    Cui, Shuna
    Chen, Shanshan
    Wu, Qingqing
    Chen, Tingting
    Li, Shihua
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 81
  • [9] Akkermansia muciniphila and its role in regulating host functions
    Derrien, Muriel
    Belzer, Clara
    de Vos, Willem M.
    [J]. MICROBIAL PATHOGENESIS, 2017, 106 : 171 - 181
  • [10] Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
    Dietrich, Peter
    Hellerbrand, Claus
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2014, 28 (04) : 637 - 653